<DOC>
	<DOCNO>NCT02254915</DOCNO>
	<brief_summary>A multi-institutional , prospective , randomised , open-label , superiority , comparative , active-controlled , phase 3 study . The study compare Synergo RF-induced hyperthermia-chemotherapy ( SHTC ) plus mitomycin C ( MMC ) standard treatment bacillus Calmette-Guérin ( BCG ) therapy first-line adjuvant treatment intermediate high-risk NMIBC , evaluate recurrence progression rate two year follow-up .</brief_summary>
	<brief_title>SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy European Urologists ' Research Operation Preserving Evolution Study I</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>1 . Patients primary intermediate highrisk papillary NMIBC accord EAU Guidelines intermediate highrisk recurrence receive BCG within previous 2 year chemotherapy treatment ( apart one early instillation ) within previous year . 2 . All clinical , intraoperative pathological item EAU risk stratification must document include bladder map . 3 . Patients must undergo reresection ( second TURB accordance EAU Guidelines ) ( ) initial TURB incomplete ( ii ) muscle specimen initial TURB ( except TaG1/LG tumour ) ( iii ) T1 G3/HG tumours TURB T1 sit must include muscle . Reresection must negative patient diagnosed T1 and/or G3/HG and/or multiple tumour initial TURB . 4 . No UC upper tract , kidney ureter . This confirm CTIVU IVU perform time initial diagnosis select case recommend late EAU guideline publish prior screen . 5 . No UC urethra , exclude visual inspection cystoscopy , addition , patient ( ) tumour trigone ( ii ) tumour bladder neck ( iii ) abnormal prostatic urethra UC must exclude biopsy prostatic urethra male patient , female patient , portion urethra adjacent bladder neck , study recruitment . 6 . All patient must urine cytology date within screen period prior randomisation . 7 . Age ≥ 18 yr 8 . Normal kidneys ureter . 9 . Pretreatment haematology biochemistry value within acceptable limit : ( ) haemoglobin ≥ 10 g/dl ( g/100 ml ) ( ii ) platelets ≥ 150 x 109/L ( 103/mm3 ) ( iii ) WBC ≥ 3.0 x 109/L ( 103/mm3 ) ( iv ) ANC ≥ 1.5 x 109/L ( 103/mm3 , absolute neutrophil count ) ( v ) Serum creatinine , SGOT , SGPT , Alkaline phosphatase : &lt; 1.5 x UNL ( upper normal limit ) 10 . Negative pregnancy test woman childbearing potential 11 . A life expectancy least duration trial . 12 . Unfit unwilling full partial cystectomy . 13 . Signed informed consent . 1 . UC involve prostatic urethra 2 . NonUC tumour urinary tract 3 . Upper tract intramural tumour ( e.g . Ostium ) . 4 . History stage &gt; T1 UC . 5 . CIS ( suspected present ) . 6 . Known suspect reduced bladder capacity . Patients US estimation maximum bladder capacity void spontaneously maximum retain bladder , use determine urine volume . A minimum volume 250 ml require . 7 . Bleeding disorder 8 . Macrohaematuria ≥ 250 RBC's/uL equivalent ( e.g . &gt; `` +++ '' erythrocytes dipstick analysis ) . 9 . Pregnant lactating woman . 10 . Women childbearing potential unwilling unable use adequate contraception sexually active . 11 . More maintenance dose oral corticosteroid ( maintenance dose define dose regimen past 6 month condition require continual corticosteroid treatment ) patient immunocompromised state reason . 12 . More lowdose Methotrexate ( &gt; 17.5 mg week ) . 13 . Other malignancy within past five year , except : nonmelanomatous skin cancer cure excision , adequately treat carcinoma situ cervix ductal CIS ( DCIS ) /lobular CIS ( LCIS ) breast stable prostate cancer ( active surveillance hormone control ) life expectancy 5 year . 14 . Any known allergy adverse event would prevent receive treatment may randomise within trial . 15 . Known untreated strictural disease bladder neck contracture condition may prevent catheterisation 21F catheter . Patients may undergo dilation urethral incision enter study . 16 . Bladder diverticulum cumulative diameter &gt; 1cm 17 . UTI time within 6 month precede randomisation . 18 . Significant urinary incontinence ( spontaneous , require use pad ) 19 . History pelvic irradiation 20 . Patients implant electronic device ( cardiac pacemaker ) unless receive permission treat physician ( e.g. , cardiologist ) monitor treat physician treatment session . 21 . Participation another study include treatment liable effect study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Synergo</keyword>
	<keyword>RITE</keyword>
	<keyword>SHTC</keyword>
	<keyword>Non Muscle Invasive Bladder Cancer</keyword>
	<keyword>NMIBC</keyword>
	<keyword>Superficial Bladder Cancer</keyword>
	<keyword>Urothelial Cell Cancer</keyword>
	<keyword>Transitional Cell Cancer</keyword>
	<keyword>Mitomycin</keyword>
</DOC>